do you need to be on glp-1 forever have stay a forever? Not necessarily., Some weight regain after stopping is common, which is why it’s important to think beyond the number on the scale. The real goal is building Are weight-loss drugs forever and

Both carry thyroid tumor warnings based on animal studies

TREATMENT TIME: Treatment time is 1 hour After care

ALTERNATIVES TO BIRTH CONTROL PILLS Patients concerned about interactions between GLP-1 medications and birth control should talk to their care providers to make sense of manufacturer recommendations and learn about alternatives to oral contraceptives

54 Similarly, in a study of 16 individuals treated with exenatide, no significant differences in the rates of GE, determined using scintigraphy, were observed between individuals who experienced GI adverse events ( e.g ., nausea) and those who did not

Resources: GLP-1 Agonists Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes Safety of Semaglutide Once-Weekly Semaglutide in Adults with Overweight or Obesity Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity Medication-Induced Gastroparesis: A Case Report Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASSCVOT design and baseline characteristics Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial Tirzepatide prevents neurodegeneration through multiple molecular pathways TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial Biology of Incretins: GLP-1 and GIP GIP and GLP1, the two incretin hormones: Similarities and differences GLP-1, GIP and glucagon receptor poly-agonists: A new era in obesity pharmacotherapy

A follow-up post hoc analysis identified improvements in fibrosis-related biomarkers in the dulaglutide group, including lower serum PRO-C6 levels for type VI collagen formation and higher urine C3M levels for type III collagen degradation (74)